T3 Companies’s Immunome IMNM Stock Holding History

T3 Companies’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,300	Closed	-$264K	–	191
2025 Q4	$264K	Buy	+12,300	New	+$216K	0.33%	62

Other funds holding IMNM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

T3 Companies's IMNM Position: Q1 2026 in Review

T3 Companies sold out of Immunome (IMNM) in Q1 2026, closing a stake of 12,300 shares — an estimated $264K sold.

T3 Companies first reported a position in IMNM in Q4 2025 and held it in 1 quarter. The position peaked at $264K in Q4 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

T3 Companies reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
T3 Companies sold 12,300 Immunome shares in Q1 2026, an estimated $264K.
T3 Companies first reported a position in Immunome in Q4 2025 and held it in 1 quarter.
T3 Companies's Immunome position peaked at $264K in Q4 2025.
202 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on T3 Companies's 13F filing for Q1 2026, filed 7 May 2026.